First Opinion

First Opinion

In generic drug plants in China and India, data falsification is still a problem

By Katherine Eban and Sony Salzman

First Opinion

Realizing the promise of prescription digital therapeutics

By Corey McCann

Opinions Plus

Early price setting, other market access planning is key for early-stage drug, device companies

By Christopher Leo, Christian Thienel, and Brendan Wang

First Opinion

I used to work on Biogen’s Alzheimer’s drug. Is the company spinning bad data?

By Ted Whitford

First Opinion

It’s time for Canada to embrace universal pharmacare and protect drug coverage from corporate erosion

By Nav Persaud and Danielle Martin

First Opinion

Vaping and prescription opioids: limbic capitalism in action

By David T. Courtwright

First Opinion

The resurgence of tuberculosis is behavioral, not medical. Nudges can fix it

By Erez Yoeli, Jon Rathauser, and David Rand

First Opinion

New diagnostic tools are essential in the battle against antibiotic resistance

By Eric Stern

First Opinion

San Francisco’s Mission Bay life science sector: pivoting with the times

By Chris Haskell

First Opinion

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

By Dennis J. Selkoe

First Opinion

Specialization improves return on capital in the life sciences

By Teresa Leste and Peter Baxendell

First Opinion

Advancing AI in health care: It’s all about trust

By Gary Marcus and Max A. Little

First Opinion

The HRA rule could be a game changer for health insurance

By Kathy Hempstead

First Opinion

Restaurants are using AI to listen in on social media. They want to know how you are feeling

By Michelle Harden

First Opinion

International pricing index ‘accomplishes nothing it sets out to do’

By Susan Peschin and Duane Schulthess

First Opinion

Put communities at the center of universal health coverage

By Gunilla Carlsson, Katie Dain, and Rico Gustav

First Opinion

Rapid expansion of telehealth comes with new challenges

By Linda A. Malek and Khaled Mowad

First Opinion

New leaders needed to translate discoveries into patient care

By Robert Lechler

First Opinion

Motherhood and medicine should mix. So why is it such a struggle?

By Qaali Hussein

First Opinion

Pelosi’s drug pricing plan puts medical innovation at risk

By Stephen J. Ubl

First Opinion

As the need for organ transplants grows, the number of transplant physicians dwindles

By David Weill

First Opinion

CBO estimate on Pelosi drug bill misses its long-term impact on health

By Dana Goldman

First Opinion

It’s time to eliminate all flavored cigarettes, not just the electronic kind

By Derek Carr and Pratima Musburger

First Opinion

Wanted: better policies and incentives to revitalize R&D for new antimicrobial drugs

By Manos Perros

First Opinion

Using CRISPR to edit eggs, sperm, or embryos does not save lives

By Tina Rulli

The health information exchange has evolved from hunter and gatherer to cultivator

The EMR has changed the doctor-patient duet into a ménage-à-trois

The ‘cancer growing in cancer medicine’: pharma money paid to doctors

Medicare’s Shared Savings Program results should have made headlines. It got a ‘collective shrug’ instead

In generic drug plants in China and India, data falsification is still a problem

Realizing the promise of prescription digital therapeutics

Early price setting, other market access planning is key for early-stage drug, device companies

I used to work on Biogen’s Alzheimer’s drug. Is the company spinning bad data?

It’s time for Canada to embrace universal pharmacare and protect drug coverage from corporate erosion

Vaping and prescription opioids: limbic capitalism in action

The resurgence of tuberculosis is behavioral, not medical. Nudges can fix it

New diagnostic tools are essential in the battle against antibiotic resistance

San Francisco’s Mission Bay life science sector: pivoting with the times

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

Specialization improves return on capital in the life sciences

Advancing AI in health care: It’s all about trust

The HRA rule could be a game changer for health insurance

Restaurants are using AI to listen in on social media. They want to know how you are feeling

International pricing index ‘accomplishes nothing it sets out to do’

Put communities at the center of universal health coverage

Rapid expansion of telehealth comes with new challenges

New leaders needed to translate discoveries into patient care

Motherhood and medicine should mix. So why is it such a struggle?

Pelosi’s drug pricing plan puts medical innovation at risk

As the need for organ transplants grows, the number of transplant physicians dwindles

CBO estimate on Pelosi drug bill misses its long-term impact on health

It’s time to eliminate all flavored cigarettes, not just the electronic kind

Wanted: better policies and incentives to revitalize R&D for new antimicrobial drugs

Using CRISPR to edit eggs, sperm, or embryos does not save lives